Transplantation Osteoporosis

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition

Volumn , Issue , 2013, Pages 495-507

  Ebeling, Peter R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Bone disease; Calcineurin inhibitors; Glucocorticoids; Immunosuppressive therapy; Transplantation osteoporosis

Indexed keywords

EID: 84988319809     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118453926.ch61     Document Type: Chapter

References (84)

1. Cohen A, Sambrook P, Shane E. 2004. Management of bone loss after organ transplantation. J Bone Miner Res 19 (12): 1919-32.
2. Cohen A, Shane E. 2003. Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int 14 (8): 617-30.
3. Nickolas TL, Cremers S, Zhang A, Thomas V, Stein E, Cohen A, Chauncey R, Nikkel L, Yin MT, Liu XS, Boutroy S, Staron RB, Leonard MB, McMahon DJ, Dworakowski E, Shane E. 2011. Discriminants of prevalent fractures in chronic kidney disease. J Am Soc Nephrol 22 (8): 1560-72.
4. Gal-Moscovici A, Sprague SM. 2007. Osteoporosis and chronic kidney disease. Semin Dial 20 (5): 423-30.
5. Stehman-Breen CO, Sherrard DJ, Alem AM, Gillen DL, Heckbert SR, Wong CS, Ball A, Weiss NS. 2000. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 58 (5): 2200-5.
6. Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C. 2000. Increased risk of hip fracture among patients with endstage renal disease. Kidney Int 58 (1): 396-9.
7. Ball AM, Gillen DL, Sherrard D, Weiss NS, Emerson SS, Seliger SL, Kestenbaum BR, Stehman-Breen C. 2002. Risk of hip fracture among dialysis and renal transplant recipients. JAMA 288 (23): 3014-8.
8. Majumdar S, Ezekowitz JA, Lix LM, Leslie W. 2012. Heart failure is a clinically and densitometrically independent and novel risk factor for major osteoporotic fractures: Population-based cohort study of 45,509 subjects. J Clin Endocrinol Metab 97 (4): 1179-86.
9. Shane E, Mancini D, Aaronson K, Silverberg SJ, Seibel MJ, Addesso V, McMahon DJ. 1997. Bone mass, vitamin D deficiency and hyperparathyroidism in congestive heart failure. Am J Med 103: 197-207.
10. Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ, Ordi J, Rimola A, Rodes J, Munoz-Gomez J. 2001. Bone disease after liver transplantation: A long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int 12 (6): 484-92.
11. Millonig G, Graziadei IW, Eichler D, Pfeiffer KP, Finkenstedt G, Muehllechner P, Koenigsrainer A, Margreiter R, Vogel W. 2005. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: A prospective single-center study. Liver Transpl 11: 960-6.
12. Ninkovic M, Love SA, Tom B, Alexander GJ, Compston JE. 2001. High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int 69 (6): 321-6.
13. Tschopp O, Boehler A, Speich R, Weder W, Seifert B, Russi EW, Schmid C. 2002. Osteoporosis before lung transplantation: Association with low body mass index, but not with underlying disease. Am J Transplant 2 (2): 167-72.
14. Keilholz U, Max R, Scheibenbogen C, Wuster C, Korbling M, Haas R. 1997. Endocrine function and bone metabolism 5 years after autologous bone marrow/ blood-derived progenitor cell transplantation. Cancer 79 (8): 1617-22.
15. Tauchmanova L, Selleri C, Rosa GD, Pagano L, Orio F, Lombardi G, Rotoli B, Colao A. 2002. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer 95 (5): 1076-84.
16. Valimaki M, Kinnunen K, Volin L, Tahtela R, Loyttniemi E, Laitinen K, Makela P, Keto P, Ruutu T. 1999. A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: Effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant 23: 355-61.
17. Kananen K, Volin L, Laitinen K, Alfthan H, Ruutu T, Valimaki MJ. 2005. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab 90: 3877-85.
18. Schulte C, Beelen D, Schaefer U, Mann K. 2000. Bone loss in long-term survivors after transplantation of hematopoietic stem cells: A prospective study. Osteoporos Int 11: 344-53.
19. Resnick J, Gupta N, Wagner J, Costa G, Cruz RJ Jr, Martin L, Koritsky DA, Perera S, Matarese L, Eid K, Schuster B, Roberts M, Greenspan S, Abu-Elmagd K. 2010. Skeletal integrity and visceral transplantation. Am J Transplan 10 (10): 2331-40.
20. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. 2000. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15: 993-1000.
21. Nikkel LE, Mohan S, Zhang A, McMahon DJ, Boutroy S, Dube G, Tanriover B, Cohen D, Ratner L, Hollenbeak CS, Leonard MB, Shane E, Nickolas TL. 2012. Reduced fracture risk with early corticosteroid withdrawal after kidney transplant. Am J Transplant 12 (3): 649-59.
22. Epstein S. 1996. Post-transplantation bone disease: The role of immunosuppressive agents on the skeleton. J Bone Miner Res 11: 1-7.
23. Ponticelli C, Aroldi A. 2001. Osteoporosis after organ transplantation. Lancet 357 (9268): 1623.
24. McIntyre HD, Menzies B, Rigby R, Perry-Keene DA, Hawley CM, Hardie IR. 1995. Long-term bone loss after renal transplantation: Comparison of immunosuppressive regimens. Clin Transplant 9 (1): 20-4.
25. Stempfle HU, Werner C, Echtler S, Assum T, Meiser B, Angermann CE, Theisen K, Gartner R. 1998. Rapid trabecular bone loss after cardiac transplantation using FK506 (tacrolimus)-based immunosuppression. Transplant Proc 30 (4): 1132-3.
26. Park KM, Hay JE, Lee SG, Lee YJ, Wiesner RH, Porayko MK, Krom RA. 1996. Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine. Transplant Proc 28 (3): 1738-40.
27. Goffin E, Devogelaer JP, Depresseux G, Squifflet JP, Pirson Y. 2001. Osteoporosis after organ transplantation. Lancet 357 (9268): 1623.
28. Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ, Rimola A, Rodes J, Munoz-Gomez J. 2001. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int 68: 83-6.
29. Singha UK, Jiang Y, Yu S, Luo M, Lu Y, Zhang J, Xiao G. 2008. Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells. J Cell Biochem 103 (2): 434-46.
30. Stein EM, Shane E. 2011. Vitamin D in organ transplantation. Osteoporos Int 22: 2107-18.
31. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarrles LD. 1991. Rapid loss of vertebral bone density after renal transplantation. N Engl J Med 325: 544-50.
32. Monier-Faugere M, Mawad H, Qi Q, Friedler R, Malluche HH. 2000. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 11: 1093-9.
33. Ramsey-Goldman R, Dunn JE, Dunlop DD, Stuart FP, Abecassis MM, Kaufman DB, Langman CB, Salinger MH, Sprague SM. 1999. Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res 14 (3): 456-63.
34. Sprague SM, Josephson MA. 2004. Bone disease after kidney transplantation. Semin Nephrol 24: 82-90.
35. Wissing KM, Broeders N, Moreno-Reyes R, Gervy C, Stallenberg B, Abramowicz D. 2005. A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation 79: 108-15.
36. Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen KG, Uhl M, Strey C, Kirste G, Olschewski M, Reichelt A, Rump LC. 2001. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 12 (7): 1530-7.
37. Kovac D, Lindic J, Kandus A, Bren AF. 2001. Prevention of bone loss in kidney graft recipients. Transplant Proc 33: 1144-5.
38. Giannini S, Dangel A, Carraro G, Nobile M, Rigotti P, Bonfante L, Marchini F, Zaninotto M, Dalle Carbonare L, Sartori L, Crepaldi G. 2001. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 16 (11): 2111-7.
39. Torres A, García S, Gómez A, González A, Barrios Y, Concepción MT, Hernández D, García JJ, Checa MD, Lorenzo V, Salido E. 2004. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int 65 (2): 705-12.
40. Miller PD. 2005. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep 3: 5-12.
41. Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen KG, Uhl M, Strey C, Kirste G, Olschewski M, Reichelt A, Rump LC. 2001. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 12 (7): 1530-7.
42. Schwarz CL, Mitterbauer CL, Heinze G, Woloszczuk W, Haas M, Oberbauer R. 2004. Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation. Kidney Int 65 (1): 304-9.
43. Palmer SC, McGregor DO, Strippoli GFM. 2007. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev (3): CD005015.
44. Chiu MY, Sprague SM, Bruce DS, Woodle ES, Thistlethwaite JR Jr, Josephson MA. 1998. Analysis of fracture prevalence in kidney-pancreas allograft recipients. J Am Soc Nephrol 9 (4): 677-83.
45. Smets YF, de Fijter JW, Ringers J, Lemkes HH, Hamdy NA. 2004. Long-term follow-up study on bone mineral density and fractures after simultaneous pancreaskidney transplantation. Kidney Int 66 (5): 2070-6.
46. Shane E, Papadopoulos A, Staron RB, Addesso V, Donovan D, McGregor C, Schulman LL. 1999. Bone loss and fracture after lung transplantation. Transplantation 68: 220-7.
47. Aris RM, Lester GE, Renner JB, Winders A, Denene Blackwood A, Lark RK, Ontjes DA. 2000. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am J Respir Crit Care Med 162 (3 Pt 1): 941-6.
48. Trombetti A, Gerbase MW, Spiliopoulos A, Slosman DO, Nicod LP, Rizzoli R. 2000. Bone mineral density in lung-transplant recipients before and after graft: Prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate. J Heart Lung Transplant 19 (8): 736-43.
49. Shane E, Rivas M, Staron RB, Silverberg SJ, Seibel M, Kuiper J, Mancini D, Addesso V, Michler RE, Factor-Litvak P. 1996. Fracture after cardiac transplantation: A prospective longitudinal study. J Clin Endocrinol Metab 81: 1740-6.
50. Leidig-Bruckner G, Hosch S, Dodidou P, Ritchel D, Conradt C, Klose C, Otto G, Lange R, Theilmann L, Zimmerman R, Pritsch M, Zeigler R. 2001. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: A follow-up study. Lancet 357: 342-7.
51. Sambrook P, Henderson NK, Keogh A, MacDonald P, Glanville A, Spratt P, Bergin P, Ebeling P, Eisman J. 2000. Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 15 (9): 1818-24.
52. Henderson K, Eisman J, Keogh A, MacDonald P, Glanville A, Spratt P, Sambrook P. 2001. Protective effect of short-tem calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation. J Bone Miner Res 16 (3): 565-71.
53. Stempfle HU, Werner C, Echtler S, Wehr U, Rambeck WA, Siebert U, Uberfuhr P, Angermann CE, Theisen K, Gartner R. 1999. Prevention of osteoporosis after cardiac transplantation: A prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 68 (4): 523-30.
54. Kapetanakis EI, Antonopoulos AS, Antoniou TA, Theodoraki KA, Zarkalis DA, Sfirakis PD, Chilidou DA, Alivizatos PA. 2005. Effect of long-term calcitonin administration on steroid-induced osteoporosis after cardiac transplantation. J Heart Lung Transplant 24 (5): 526-32.
55. Bianda T, Linka A, Junga G, Brunner H, Steinert H, Kiowski W, Schmid C. 2000. Prevention of osteoporosis in heart transplant recipients: A comparison of calcitriol with calcitonin and pamidronate. Calcif Tissue Int 67: 116-21.
56. Gil-Fraguas L, Jodar E, Martinez G, Escalona MA, Vara J, Robles E, Hawkins F. 2005. Evolution of bone density after heart transplantation: Influence of anti-resorptive therapy. J Bone Miner Res 20 (Suppl 1): S439-40.
57. Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR, Obermayer-Pietsch BM, Pilz S, Dimai HP, Prenner G, Tscheliessnigg KH, Hauge E, Portugaller RH, Dobnig H. 2009. Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: A randomized double-blind, placebo-controlled trial. J Bone Miner Res. 24: 1335-44.
58. Shane E, Addesso V, Namerow PB, McMahon, DJ, Lo SH, Staron RB, Zucker M, Pardi S, Maybaum S, Mancini D. 2004. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 350: 767-76.
59. Cohen A, Addesso V, McMahon DJ, Staron RB, Namerow P, Maybaum S, Mancini D, Shane E. 2006. Discontinuing antiresorptive therapy one year after cardiac transplantation: Effect on bone density and bone turnover. Transplantation 81: 686-91.
60. Mitchell MJ, Baz MA, Fulton MN, Lisor CF, Braith R. 2003. Resistance training prevents vertebral osteoporosis in lung transplant recipients. Transplantation 76: 557-62.
61. Braith RW, Magyari PM, Fulton MN, Lisor CF, Vogel SE, Hill JA, Aranda JM Jr. 2006. Comparison of calcitonin versus calcitonin and resistance exercise as prophylaxis for osteoporosis in heart transplant recipients. Transplantation 81: 1191-5.
62. Ninkovic M, Skingle SJ, Bearcroft PW, Bishop N, Alexander CJ, Compston JE. 2000. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation. Eur J Gastroenterol Hepatol 12 (8): 931-5.
63. Hommann M, Abendroth K, Lehmann G, Patzer N, Kornberg A, Voigt R, Seifert S, Hein G, Scheele J. 2002. Effect of transplantation on bone: Osteoporosis after liver and multivisceral transplantation. Transplant Proc 34 (6): 2296-8.
64. Crawford BA, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, McCaughan GW. 2006. Zoledronic acid prevents bone loss after liver transplantation: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 144 (4): 239-48.
65. Bodingbauer M, Wekerle T, Pakrah B, Roschger P, Peck-Radosavljevic M, Silberhumer G, Grampp S, Rockenschaub S, Berlakovich G, Steininger R, Klaushofer K, Oberbauer R, Muhlbacher F. 2007. Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation. Am J Transplant 7: 1763-69.
66. Monegal A, Guanabens N, Suarez MJ, Suarez F, Clemente G, Garcia-Gonzalez M, De la Mata M, Serrano T, Casafont F, Torne S, Barrios C, Navasa M. 2009. Pamidronate in the prevention of bone loss after liver transplantation: A randomized controlled trial. Transpl Int 22: 198-206.
67. Kaemmerer D, Lehmann G, Wolf G, Settmacher U, Hommann M. 2010. Treatment of osteoporosis after liver transplantation with ibandronate. Transpl Int 23: 753-9.
68. Karasu Z, Kilic M, Tokat Y. 2006. The prevention of bone fractures after liver transplantation: Experience with alendronate treatment. Transplant Proc 38: 1448-52.
69. Awan KS, Wagner JM, Martin D, Medich DL, Perera S, Abu Elmagd K, Greenspan SL. 2007. Bone loss following small bowel transplantation. ASBMR 29th Annual Meeting. J Bone Miner Res 22: s352-s401. Abstract T497, s356.
70. BanfiA, Podesta M, Fazzuoli L, Sertoli MR, Venturini M, Santini G, Cancedda R, Quarto R. 2001. High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: A mechanism for postbone marrow transplantation osteopenia. Cancer 92 (9): 2419-28.
71. Lee WY, Cho SW, Oh ES, Oh KW, Lee JM, Yoon KH, Kang MI, Cha BY, Lee KW, Son HY, Kang SK, Kim CC. 2002. The effect of bone marrow transplantation on the osteoblastic differentiation of human bone marrow stromal cells. J Clin Endocrinol Metab 87 (1): 329-35.
72. Ebeling P, Thomas D, Erbas B, Hopper L, Szer J, Grigg A. 1999. Mechanism of bone loss following allogeneic and autologous hematopoeitic stem cell transplantation. J Bone Miner Res 14: 342-50.
73. Ebeling PR. 2005. Bone disease after bone marrow transplantation. In: Compston J, Shane E (eds.) Bone Disease of Organ Transplantation. San Diego: Elsevier Academic Press. Chapter 19. pp. 339-52.
74. Lee WY, Kang MI, Baek KH, Oh ES, Oh KW, Lee KW, Kim SW, Kim CC. 2002. The skeletal site-differential changes in bone mineral density following bone marrow transplantation: 3-year prospective study. J Korean Med Sci 17 (6): 749-54.
75. Gandhi MK, Lekamwasam S, Inman I, Kaptoge S, Sizer L, Love S, Bearcroft PW, Milligan TP, Price CP, Marcus RE, Compston JE. 2003. Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: Long-term follow-up of a prospective study. Br J Haematol 121: 462-8.
76. Ebeling PR. 2005. Is defective osteoblast function responsible for bone loss from the proximal femur despite pamidronate therapy? J Clin Endocrinol Metab 90: 4414-6.
77. Tauchmanova L, De Rosa G, Serio B, Fazioli F, MainolfiC, Lombardi G, Colao A, Salvatore M, Rotoli B, Selleri C. 2003. Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: A single center experience and a review. Cancer 97: 2453-61.
78. Tauchmanova L, Selleri C, Esposito M, Di Somma C, Orio F Jr, Bifulco G, Palomba S, Lombardi G, Rotoli B, Colao A. 2003. Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. Osteoporos Int 14: 1013-9.
79. Tauchmanova L, Ricci P, Serio B, Lombardi G, Colao A, Rotoli B, Selleri C. 2005. Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. J Clin Endocrinol Metab 90: 627-34.
80. Grigg AP, Shuttleworth P, Reynolds J, Schwarer AP, Szer J, Bradstock K. 2006. Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab 91 (10): 3835-43.
81. D ' Souza AB, Grigg AP, Szer J, Ebeling PR. 2006. Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation. Int Med J 36: 600-3.
82. Stein EM, Ortiz D, Jin Z, McMahon DJ, Shane E. 2011. Prevention of fractures after solid organ transplantation: A meta-analysis. J Clin Endocrinol Metab 96: 3457-65.
83. Rickard DJ, Wang FL, Rodriguez-Rojas AM, Wu Z, Trice WJ, Hoffman SJ, Votta B, Stroup GB, Kumar S, Nuttall ME. 2006. Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells. Bone 39 (6): 1361-72.
84. Chan GK, Miao D, Deckelbaum R, Bolivar I, Karaplis A, Goltzman D. 2003. Parathyroid hormone-related peptide interacts with bone morphogenetic protein 2 to increase osteoblastogenesis and decrease adipogenesis in pluripotent C3H10T mesenchymal cells. Endocrinology 144: 5511-20.